Mindfulness for preventing psychosis in young people at high risk
Part of Mental health clinical trials.
This study tests whether a mindfulness program can help prevent psychosis in young people who are at ultra high risk. The goal is to see if learning mindfulness skills can protect your mental health and keep symptoms from getting worse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 30 years old.
- You must have an 'ultra high risk' for psychosis (or have had brief or unusual psychotic experiences) as confirmed by a specialist.
- Your symptoms must be affecting your daily life, such as work, school, or social activities.
- You must not have had a previous diagnosis of schizophrenia, schizoaffective disorder, or bipolar disorder.
- You must not have taken antipsychotic medication for more than 12 months in the past.
- You must be able to communicate in French and be willing to provide consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study explores how young people who are at high risk for psychosis or have had a first episode experience mindfulness. It uses interviews to understand their personal experience, which could help improve future treatments.
This trial tests a telehealth (video/phone) version of cognitive behavioral therapy to help young people who are at risk for developing psychosis. It may help by teaching skills to reduce symptoms and improve coping, with support from a key family or close person.
This study tests a new program to help young people who have early signs of psychosis and have had thoughts of suicide or tried to harm themselves. The program works with the young person and a family member or caregiver to improve support and reduce suicide risk.
This study tests a support program for young people in Tunisia who show early signs of possible psychosis. It aims to help them before more serious symptoms develop.
This study tests whether a medication called cannabidiol (a non-intoxicating compound from cannabis) can help reduce symptoms and prevent progression in young people at clinical high risk for psychosis. Participants will receive either the study drug or a placebo (a pill with no active ingredient) and will be followed to see how they respond.
This study is testing a new French version of a questionnaire (SPI-CY) that helps doctors better understand early signs of psychosis in teenagers. If you are 12 to 17 and already being checked for these signs, you may be able to help improve the tool.
Hear when a new Clinical High Risk for Psychosis (CHR) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.